A representative walks into a Harare surgery with a glossy visual aid, a new WhatsApp campaign on his phone and a target hanging over his head. The doctor asks one question: “Where is the evidence for that claim?”
That is where many sales calls become uncomfortable.
MCAZ medicine promotion rules are not paperwork for the regulatory team to worry about after the campaign has gone live. They shape what a pharmaceutical representative can say, show, send and leave behind in Zimbabwe.
Good pharmaceutical sales training must teach people how to sell with confidence and evidence. A rep who knows the product, the approved claim and the customer wins trust. A rep who improvises medical claims can put the company, the product and their own career in trouble.
Calm down.
You can still sell. You just need to sell clean.
MCAZ is watching more than the printed advert
The Medicines Control Authority of Zimbabwe, MCAZ, regulates medicine promotion in Zimbabwe. Its current advertising guideline, MCAZ/LED/GL-18 Revision 1, took effect in October 2024 and replaced the July 2022 revision.
The common mistake is thinking advertising means a newspaper advert or a radio slot.
For a pharma rep, promotion includes detailing in a doctor’s room, a PowerPoint presentation, a leave-behind, a clinic poster, a WhatsApp post and verbal claims during a call. If it helps persuade someone to prescribe, recommend, stock or buy a medicine, treat it as promotion.
That matters because no medicine may be advertised without MCAZ’s written approval. New promotional material must go to MCAZ before use. Changed material must also go back before use.
A changed visual is not “the same artwork”.
If you changed the claim, wording, price message or design, you changed the promotional material. The old L&A reference number does not magically cover the new version.
MCAZ may give an applicant up to 60 days to resolve outstanding matters. If they are not resolved in that period, the application is refused. After MCAZ makes its decision, it communicates that decision within 10 working days.
Build that waiting time into the campaign calendar. Do not print 5,000 brochures first and ask questions later.
The document in your bag must match the registered product
Your promotion must concern a medicine legally available in Zimbabwe. It must be accurate, balanced, current and supported by evidence. More importantly, it must agree with the MCAZ-approved scientific data sheet, package insert and conditions of registration.
That last part catches people.
A sales manager may want a sharper claim because the competitor is making noise. The marketing team may want a shorter WhatsApp caption because people do not read long text. Neither reason changes what the product is approved to say.
The scientific data sheet and package insert are your fence. Stay inside it.
What a responsible detailing call should contain
A proper professional promotion needs more than a brand name and a smiling patient.
Your sales aid should provide the active ingredient or approved generic name, brand name, strength, approved uses and dosage form or regimen. It should also cover key adverse reactions, contraindications, warnings, interactions, manufacturer or distributor details and suitable scientific references.
Yes, the risks too.
Some reps fear that mentioning warnings will kill the sale. In professional medicine promotion, hiding material risk kills trust faster. A clinician needs enough information to make a sound decision for a patient.
If you say a medicine is “safe”, qualify that statement and support it. If you say it is better than another product, the comparison must be fair, factual and substantiated.
“Best in Zimbabwe” is not evidence.
“Works faster” is not evidence either, unless the approved data supports the exact comparison you are making.
Prescription medicines are for professional audiences
Prescription-only medicines may be advertised only in an MCAZ-approved professional journal or directly to medical, dental, veterinary or pharmaceutical professionals. They must not be advertised to the general public.
This is where a casual Facebook post can become a serious problem.
A public page has no gatekeeper. Your patient, your aunt, a schoolchild and a regulator can all see it. If the product is prescription-only, a public post promoting it is the wrong road.
The same caution applies to a WhatsApp status. “It is just my contacts” is not a compliance system.
If you are detailing to a pharmacist in Bulawayo, speak professionally and use approved material. If you are posting content that can reach the public, stop and check whether the medicine may be promoted there at all.
Two calls that show the difference
Take a Harare-based distributor preparing a campaign for a newly registered prescription medicine. The team creates a doctor-detailing aid, then turns the headline into a public social-media post because the brand manager wants quick awareness. They have crossed into public promotion of a prescription-only medicine. The better move is to submit the professional material to MCAZ first, use it only with the permitted professional audience, and keep public communication away from product promotion.
The cost of getting this wrong is bigger than a rejected post. False or misleading advertising, or breaching prescription-medicine advertising restrictions, can be an offence carrying a fine of up to level 12, imprisonment of up to two years, or both. That is why a rep should never treat “just post it” as a harmless instruction.
Now take a Bulawayo pharmacy chain with a sales team pushing an over-the-counter medicine. A rep wants to announce a public discount in USD and ZiG pricing, then add a free item for customers who buy two packs. Medicine advertising or sales must not include a bonus offer or public discount. The team should rather seek regulatory guidance and use only MCAZ-approved communication before any campaign goes live.
The lesson is not that pricing conversations are forbidden in business. The lesson is that medicines sit in a regulated category, and ordinary retail tricks can become expensive mistakes.
Gifts, education and the prescriber trap
A rep is under pressure. Quarter-end is close. A doctor has influence. Someone suggests a “small appreciation” to encourage more prescriptions.
No.
MCAZ guidance says you must not offer or seek financial or material benefits to influence prescribing. You also cannot disguise promotional material as education. Medicines must be excluded from purchase-to-qualify promotions.
A CME event can be useful. Training can be useful. Scientific discussion can be useful.
But if the real purpose is to hide a sales pitch or reward prescribing, the room knows. Regulators know too.
Your people should be able to explain the difference between education and promotion. Education informs without concealing the commercial purpose. Promotion sells openly, within approved claims and with the required safety information.
Do not try to be clever with labels.
The officer reviewing the material will look at what it actually says, what it leaves out and what it is trying to make the audience do.
Build a field system before reps enter the streets
Compliance should not live in one exhausted regulatory affairs person’s inbox. It needs a field system.
Start with one approved master folder for every brand. It should contain the MCAZ-approved advertisement, its L&A reference number, the approved scientific data sheet, package insert and current detailing guide. A rep must know where to find these documents before walking into a practice.
Then give every rep a simple pre-call check:
● Is this product legally available in Zimbabwe?
● Is this exact visual or message MCAZ-approved?
● Is my audience permitted to receive this promotion?
● Can I support every claim with approved scientific information?
● Have I included the relevant warnings, interactions and adverse reactions?
Do not make the checklist a decoration in a training room. Make it part of call planning, ride-alongs and sales manager reviews.
A sales manager should occasionally ask a rep to explain a claim without reading from the brochure. If the rep cannot explain the approved indication, contraindications or interaction warning, they are not ready to present the product alone.
That is not punishment.
That is protecting patients, customers and the business.
The mistake everyone skips
Most teams check the artwork once. They forget to control copies.
Old brochures remain in car boots. A former employee keeps a PowerPoint. A WhatsApp PDF gets forwarded for two years. Then the registered product information changes, but the field keeps talking from yesterday’s material.
Create a withdrawal process. When material changes, collect or destroy the old copies, remove old files from shared drives and tell the field team exactly what has been replaced. A version date on the material helps, because a rep can see immediately whether they are carrying the current item.
What changed and what has stayed firm
The rules did not suddenly arrive in October 2024. The written-approval requirement, restrictions on codeine-containing medicines and psychotropic substances, and the prohibition on bonus offers or public discounts have deeper legal roots.
What changed recently is the operative MCAZ advertising guidance. As of October 2026, MCAZ/LED/GL-18 Revision 1 remains the current guideline identified in the MCAZ materials reviewed for this article.
| Change or control | Position for Zimbabwe pharma reps | What you do daily | | October 2024 guideline | MCAZ/LED/GL-18 Revision 1 replaced the July 2022 revision | Train from the current approved material, not an old slide deck | | Written approval | No medicine may be advertised without MCAZ written approval | Confirm the L&A reference before using a visual or message | | Changed promotion | New or changed promotional material needs approval before use | Stop using it until approval is in place | | Prescription-only promotion | Limited to approved professional journals or specified healthcare professionals | Keep it out of public social media and public-facing campaigns | | Claims and comparisons | Must be accurate, balanced, current and substantiated | Use the approved indication and evidence, not competitor gossip | | Gifts and incentives | Benefits must not influence prescribing | Decline the shortcut, document concerns and escalate them | Codeine-containing medicines and psychotropic substances may not be advertised. If your portfolio touches either category, do not assume a normal campaign route applies. Ask the regulatory team to confirm the position before any promotion is drafted.
Frequently Asked Questions
Can a pharma rep send product information by WhatsApp?
WhatsApp content can be promotion. Check the audience, the medicine category and whether the exact material has MCAZ approval before sending it. A prescription-only medicine must not be promoted to the general public.
Can I use an old MCAZ-approved brochure if only the price changed?
No. A changed price message is a changed promotional item under the common compliance risks identified by MCAZ guidance. Submit changed material for approval before using it.
May I call a medicine “safe” during a doctor call?
Only with proper qualification and evidence consistent with the approved scientific information. “Safe” on its own can mislead because every medicine has circumstances, warnings or adverse-reaction considerations.
Can we offer a free item when a customer buys medicine?
No. Medicines may not be advertised or sold with a bonus offer or public discount. Do not build purchase-to-qualify promotions around medicines.
The best pharma reps do not win by making the loudest claim in the room. They win because doctors, pharmacists and business leaders trust what comes out of their mouths.
Train your team before the wrong WhatsApp post, the careless clinic poster or the desperate quarter-end gift becomes a regulatory problem.
Request a sales training or consulting proposal for your pharmaceutical team. What would happen to your sales call tomorrow if every claim had to survive an MCAZ review?
